home / stock / nvo / nvo articles

NVO Articles, Novo Nordisk A/S - From 04/03/24

Stock Information
Company Name: Novo Nordisk A/S
Stock Symbol: NVO
Market: NYSE
Website: novonordisk.com
Menu
NVO NVO Quote NVO Short NVO News NVO Articles NVO Message Board
Get NVO Alerts

News, Short Squeeze, Breakout and More Instantly...
Eli Lilly Struggles To Keep Pace With Mounjaro, Zepbound Demand: 'Currently Unavailable' On Amazon Pharmacy | Benzinga

After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company (NYSE:LLY) stock h...
Novo Nordisk's Popular Diabetes Drug Ozempic Starter Kits Face Extended Shortages in Germany, Faces Biosimilar Threat In China | Benzinga

Novo Nordisk A/S (NYSE:NVO) has reportedly warned, indicating that starter kits for its widely used diabetes drug Ozempic (semaglutide) will n...

Costco Long Known For Rotisserie Chicken And Hot Dogs Counters Junk Food With Weight Loss Plan To Help You Shed Those Extras | Benzinga

Costco Wholesale Corporation (NASDAQ:COST) has launched a weight management program to help its members in their weight loss journey. The program w...

AstraZeneca CEO Highlights Decade-Long Sales Goal Of $45B Along With Investor Doubts As It Lags In Weight Loss Race | Benzinga

AstraZeneca Plc’s (NASDAQ:AZN) Chief Executive Pascal Soriot says the company achieved a significant milestone by reaching a s...
Citi Monitors Competitive Threats To Eli Lilly, Says It Is Positioned To Maintain Leadership And Expand | Benzinga

Citi Research has increased the price target for Eli Lilly And Co (NYSE:LLY), reflecting increased anticipated risk-adjusted peak sa...

Bernie Sanders Slams 'Outrageous' Prices Of Miracle Weight Loss Drug Ozempic, Mulls Meeting With Novo Nordisk CEO | Benzinga

Sen. Bernie Sanders (I-Vt.) has taken a stand against the "outrageous" prices of diabetes drug Ozempic by Novo Nordisk (NYSE:NVO). He is considerin...

Bitcoin Vs. Gold Vs. SPY: Which Asset Class Would've Given Best Returns On $1000 Investment In Q1? | Benzinga

The first quarter of 2024 has turned out to be a blockbuster for most asset classes, and the strong performances have left investors worried abou...
Did Bitcoin, Gold Or S&P 500 Make You Richer This Quarter? What $1000 Invested In These Asset Classes Would've Returned | Benzinga

The first quarter of 2024 has turned out to be a blockbuster for most asset classes, and the strong performances have left investors worried abou...

Scholar Rock Is A Potential M&A Target, Its Exploration of Obesity Market Garners Interest: Analyst | Benzinga

Raymond James has initiated coverage on Scholar Rock Holding (NASDAQ:SRRK), supported by the potential value with a couple of key pr...

How Much Does It Cost To Make Novo Nordisk's Ozempic? Shockingly Low Against $1,000 Price Tag, Study Shows | Benzinga

A recent study suggests that despite Novo Nordisk A/S’s (NYSE:NVO) high monthly charge of close to $1,000 for its blockbuster diabe...
Previous 10 Next 10